Cargando…

Introducing Immunotherapy Advances

Detalles Bibliográficos
Autor principal: Elliott, Tim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585662/
https://www.ncbi.nlm.nih.gov/pubmed/36284897
http://dx.doi.org/10.1093/immadv/ltaa009
_version_ 1784813542116950016
author Elliott, Tim
author_facet Elliott, Tim
author_sort Elliott, Tim
collection PubMed
description
format Online
Article
Text
id pubmed-9585662
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95856622022-10-24 Introducing Immunotherapy Advances Elliott, Tim Immunother Adv Editorial Oxford University Press 2020-11-25 /pmc/articles/PMC9585662/ /pubmed/36284897 http://dx.doi.org/10.1093/immadv/ltaa009 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Immunology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Editorial
Elliott, Tim
Introducing Immunotherapy Advances
title Introducing Immunotherapy Advances
title_full Introducing Immunotherapy Advances
title_fullStr Introducing Immunotherapy Advances
title_full_unstemmed Introducing Immunotherapy Advances
title_short Introducing Immunotherapy Advances
title_sort introducing immunotherapy advances
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585662/
https://www.ncbi.nlm.nih.gov/pubmed/36284897
http://dx.doi.org/10.1093/immadv/ltaa009
work_keys_str_mv AT elliotttim introducingimmunotherapyadvances